On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Zenosense, Inc. (ZENO) Well Positioned to Capitalize on Accelerated Market Penetration of Point-of-Care Diagnostics Devices

  • POC devices speed up triage, diagnosis and treatment of patients
  • MIDS Cardiac™ is being developed to detect the biomarker troponin I or T for suspected heart attack within 3 minutes, as opposed to often taking 60 minutes in central laboratories
  • Global cardiac biomarkers market expected to reach $13.3 billion by 2024

A recent report by Grand View Research analyzes the shortage of skilled medical staff and how this is expected to accelerate the market penetration rate of point-of-care (POC) diagnostic products (http://nnw.fm/NB6pp). The major advantage of these devices is that they can be operated by both qualified medical professionals and non-medical personnel with minimal training. Through its joint venture ownership of MIDS Medical Limited (MML), Zenosense, Inc. (OTC: ZENO) is developing “MIDS”, a nano-magnetic detection technology to allow true laboratory accuracy at the POC. This groundbreaking technology, if successfully embodied in a POC device, strongly positions Zenosense to capitalize on the predicted global growth in this market.

In the United States, development funding for diagnostics is being provided by many institutions, including the National Institutes of Health (NIH), the Department of Defense (DOD) and private foundations such as the Bill and Melinda Gates Foundation.

MIDS development is carried out at MML’s laboratories at the Sci-Tech Daresbury campus in the UK, a facility that’s internationally recognized for leading-edge scientific research and commercial development. MML has exclusive rights to the MIDS technology platform through patents already granted in China and the United States. The company has also filed patent applications in all other key geographic areas around the world.

The MIDS technology uses nano-magnets to detect and quantify assay beads instead of the conventional optical detection method, with the MIDS “Lab-on-Chip” technology designed as an equally accurate, cost effective and much faster alternative to laboratory analysis.

POC devices have the capability to expedite laboratory testing, saving medical personnel crucial time in time-sensitive situations. MML is currently focused on the initial development and commercialization of its MIDS Cardiac POC technology. This project aims to deliver a handheld device using a disposable test strip for rapid detection of suspected heart attack, or acute myocardial infarction (AMI).

MIDS Cardiac is being developed for use by minimally trained emergency response personnel to speed up triage, diagnosis and treatment of patients suffering suspected symptoms of this life threatening condition. The technology aims to detect extremely low levels of cardiac biomarkers, including troponin, the medical profession’s biomarker of choice for AMI.

Currently, high sensitivity troponin assays can only be conducted in central laboratories using expensive equipment, and they typically take 60 minutes to turn around results. MML’s solution is being developed to be cost-effective, with the ability to produce troponin results within three minutes and more extensive biomarker testing expected to be provided within eight minutes.

Zenosense, through MML, intends to develop wider applications of its MIDS technology platform to include POC immunoassay testing of many other medical conditions and diseases. MML’s test results on its Hybrid Strip development system already indicate that MML can detect commercially available assay beads at extremely low levels. The successful incorporation of magnetic detection should provide a significant improvement in accuracy over existing POC devices that are limited to imperfect optical detection, which cannot equal laboratory analyzer performance.

The system uniquely positions Zenosense to capitalize on a fast-growing market. According to Grand View Research, the global cardiac biomarkers market is expected to reach $13.3 billion by 2024, and Markets and Markets report that the global immunoassay testing market is projected to be worth $25.45 billion by 2021.

For more information, visit the company’s website at www.Zenosense.com

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Archives

Select A Month

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217